How Bullish Analyst Coverage and New Capital Raise Could Impact Olema Pharmaceuticals (OLMA) Investors

Simply Wall St

Thu, January 8, 2026 at 9:09 PM EST 3 min read

• Olema Pharmaceuticals has recently attracted bullish analyst attention, with UBS initiating coverage and Citi reiterating its positive stance as the company advances Phase 3 and Phase 1 oncology trials supported by fresh capital from a November 2025 public offering of about US$218.50 million.

• This cluster of optimistic research views and Olema’s strengthened funding position underscores growing market focus on potential near-term clinical and regulatory milestones in its breast cancer pipeline.

• Next, we’ll examine how the upbeat analyst coverage and upcoming 90-day catalyst watch could shape Olema Pharmaceuticals’ investment narrative.

The latest GPUs need a type of rare earth metal called Neodymium and there are only 39 companies in the world exploring or producing it. Find the list for free.

For Olema to make sense in a portfolio, an investor has to believe that its lead breast cancer candidate, palazestrant, and earlier‑stage OP‑3136 can eventually justify a business that today has no revenue and is running sizeable losses. The recent wave of upbeat analyst coverage, capped by UBS initiating with a positive stance and Citi lifting its target and adding Olema to a 90‑day catalyst watch, sharpens attention on nearer term clinical readouts and regulatory steps as the key share price drivers. The November 2025 equity raise of about US$218.5 million reduces immediate funding pressure, which may ease one prior risk, but it also reinforces how dependent the story remains on trial execution and data quality. At the same time, a very strong one‑year share price run and ongoing cash burn keep valuation risk and future dilution firmly in view.

However, investors should not overlook one risk that sits behind the recent optimism. Olema Pharmaceuticals’ shares have been on the rise but are still potentially undervalued by 16%. Find out what it’s worth.

Three fair value views from the Simply Wall St Community span roughly US$4.53 to US$45.30, showing how far apart individual models sit. Set against the recent analyst enthusiasm and heightened 90‑day catalyst focus, this wide spread underlines how differently future trial outcomes and funding needs could play out for Olema.

Explore 3 other fair value estimates on Olema Pharmaceuticals – why the stock might be worth as much as 77% more than the current price!

Disagree with this assessment? Create your own narrative in under 3 minutes – extraordinary investment returns rarely come from following the herd.